1 unchanged sentence
Sales of Unregistered Securities
−Removed: On February 14, 2020, we granted stock options to one new employee to purchase 4,000 shares of our common stock at an exercise price of $6.50 per share.
−Removed: These options were inducement grants made outside of our 2017 Equity
−Removed: Incentive Plan in accordance with Nasdaq Listing Rule 5635 (c)(4) and Section 4(a)(2) of the Securities Act of 1933, as amended.
−Removed: The options have a ten-year term and vest over four years, with 25% of the shares underlying the option award vesting on the one-year anniversary of the applicable employee’s new hire date and the remaining 75% of the shares underlying the award vesting monthly thereafter for three-years.
−Removed: Vesting of the options is subject to the employee’s continued service with our company through the applicable vesting date.
+Added: On April 15, 2020, we granted stock options to two new employees to purchase 8,000 shares of our common stock at an exercise price of $9.35 per share.
+Added: These options were inducement grants made outside of our 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635 (c)(4) and Section 4(a)(2) of the Securities Act of 1933, as amended.
+Added: The options have a ten-year term and vest over four years, with 25% of the shares underlying the option award vesting on the one-year anniversary of the applicable employee’s new hire date and the remaining 75% of the shares underlying the award vesting monthly thereafter for three-years.
+Added: Vesting of the options is subject to the employee’s continued service with our company through the applicable vesting date.
We intend to file a registration statement on a Form S-8 to register the sh ares of common stock underlying these options prior to the time at which these options become exercisable.
3 unchanged sentences
Exhibit Index
−Removed: EXHIBIT 10.1*+
−Removed: Amendment No.
−Removed: 2 to Commercial Supply Agreement, dated March 27, 2020, by and between the Registrant and Catalent Pharma Solutions, LLC
+Added: Amended and Restated Sales Agreement, dated May 7, 2020, by and between the Registrant and Jefferies LLC (incorporated by reference to Exhibit 1.2 to the Registrant’s Registration Statement on Form S-3 (File No.
+Added: 333-238087) filed on May 7, 2020).
EXHIBIT 10.2*+
−Removed: Form of Non-Employee Director Restricted Stock Unit Award under 2017 Equity Incentive Plan
+Added: Fifth Amendment to Exclusive License Agreement, date July 6, 2020, by and between the Johns Hopkins University and the Registrant .
EXHIBIT 10.3+
−Removed: Form of Non-Employee Director Deferred Restricted Stock Unit Award under 2017 Equity Incentive Plan
+Added: Form of Employee Restricted Stock Unit Award under 2017 Equity Incentive Plan
+Added: 2017 Equity Inventive Plan, as amended (incorporated by reference to Exhibit 99.1 to the Registrant’s Current Report on Form 8-K (File No.
+Added: 001-38150) filed on June 26, 2020).
EXHIBIT 31.1+
9 unchanged sentences
EXHIBIT 101.INS
−Removed: XBRL Instance Document.
+Added: Inline XBRL Instance Document.
+Added: (the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document)
EXHIBIT 101.SCH
−Removed: XBRL Taxonomy Extension Schema Document.
+Added: Inline XBRL Taxonomy Extension Schema Document.
EXHIBIT 101.CAL
−Removed: XBRL Taxonomy Extension Calculation Linkbase Document.
+Added: Inline XBRL Taxonomy Extension Calculation Linkbase Document.
EXHIBIT 101.DEF
−Removed: XBRL Taxonomy Extension Definition Linkbase Document.
+Added: Inline XBRL Taxonomy Extension Definition Linkbase Document.
EXHIBIT 101.LAB
−Removed: XBRL Taxonomy Extension Label Linkbase Document.
+Added: Inline XBRL Taxonomy Extension Label Linkbase Document.
EXHIBIT 101.PRE
−Removed: XBRL Taxonomy Extension Presentation Linkbase Document.
+Added: Inline XBRL Taxonomy Extension Presentation Linkbase Document.
+Added: Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).
* Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
2 unchanged sentences
KALA PHARMACEUTICALS, INC.
+Added: August 6, 2020
/s/ Mark Iwicki
Chairman of the Board, Chief Executive Officer and President (Principal Executive Officer)
+Added: August 6, 2020
/s/ Mary Reumuth
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.